NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
June 30, 2016
(unaudited)
NOTE 1. - NATURE OF BUSINESS AND SUMMARY OF SIGNIFICANT
ACCOUNTING POLICIES
Basis of Presentation
-
The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted
accounting principles (GAAP) for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not
include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management,
all adjustments consisting of normal recurring accruals considered necessary for a fair and non-misleading presentation of the
financial statements have been included.
Operating results for the six months ended
June 30, 2016 are not necessarily indicative of the results that may be expected for the year ending December 31, 2016. The
balance sheet at December 31, 2015 has been derived from the audited consolidated financial statements at that date, but
does not include all of the information and footnotes required by GAAP for complete financial statements. These interim consolidated
financial statements should be read in conjunction with the December 31, 2015 audited consolidated financial statements and the
notes thereto.
Principles of Consolidation
-
The accompanying consolidated financial statements include the accounts of 22nd Century Group, Inc. (“22nd Century
Group”), its three wholly-owned subsidiaries, 22nd Century Limited, LLC (“22nd Century Ltd”), NASCO Products,
LLC (“NASCO”), and Botanical Genetics, LLC (“Botanical Genetics”), and two wholly-owned subsidiaries of
22nd Century Ltd, Goodrich Tobacco Company, LLC (“Goodrich Tobacco”) and Hercules Pharmaceuticals, LLC (“Hercules
Pharma”) (collectively, “the Company”). All intercompany accounts and transactions have been eliminated.
Nature of Business
-
22nd Century Ltd is a plant biotechnology company specializing in technology that allows for the level of nicotine and other
nicotinic alkaloids (e.g., nornicotine, anatabine and anabasine) in tobacco plants to be decreased or increased through genetic
engineering and plant breeding. The Company currently owns or exclusively controls more than 200 issued patents and more than
50 pending patent applications around the world. Goodrich Tobacco and Hercules Pharma are business units for the Company’s
(i) premium cigarettes and potential modified risk tobacco products and (ii) smoking cessation product, respectively. The Company
acquired the membership interests of NASCO on August 29, 2014. NASCO is a federally licensed tobacco products manufacturer, a
participating member of the tobacco Master Settlement Agreement (“MSA”) between the tobacco industry and the Settling
States under the MSA, and operates the Company’s cigarette manufacturing business in North Carolina. Botanical Genetics
is a wholly-owned subsidiary of 22nd Century Group, and was incorporated to facilitate an equity investment more fully described
in Note 7.
Reclassifications
-
Certain items in the 2015 financial statements have been reclassified to conform to the 2016 classification.
Preferred stock authorized
-
The Company is authorized to issue “blank check” preferred stock, which could be issued with voting, liquidation,
dividend and other rights superior to our common stock.
Accounts receivable
- The
Company periodically reviews aged account balances for collectability. As of June 30, 2016 and December 31, 2015, the Company
has established an allowance for doubtful accounts in the amount of $10,000.
Inventory
-
Inventories
are valued at the lower of cost or market. Cost is determined using an average cost method for tobacco leaf inventory and the
first-in, first-out (FIFO) method on all other inventories. Inventories are evaluated to determine whether any amounts are
not recoverable based on slow moving or obsolete condition and are written off or reserved as appropriate. Inventories at June
30, 2016 and December 31, 2015 consisted of the following:
|
|
June 30,
2016
|
|
|
December 31,
2015
|
|
|
|
|
|
|
|
|
Inventory - tobacco leaf
|
|
$
|
1,842,822
|
|
|
$
|
1,816,857
|
|
Inventory - finished goods
|
|
|
|
|
|
|
|
|
Cigarettes and filtered cigars
|
|
|
560,819
|
|
|
|
342,707
|
|
Inventory - raw materials
|
|
|
|
|
|
|
|
|
Cigarette and filtered cigar components
|
|
|
853,915
|
|
|
|
657,389
|
|
|
|
|
3,257,556
|
|
|
|
2,816,953
|
|
Less: inventory reserve
|
|
|
110,623
|
|
|
|
110,623
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
3,146,933
|
|
|
$
|
2,706,330
|
|
Fixed assets
-
Fixed
assets are recorded at their acquisition cost and depreciated on a straight-line basis over their estimated useful lives ranging
from 3 to 10 years. Depreciation commences when the asset is placed in service.
Intangible Assets
-
Intangible
assets are recorded at cost and consist primarily of (1) expenditures incurred with third parties related to the processing of
patent claims and trademarks with government authorities, as well as costs to acquire patent rights from third parties, (2) license
fees paid for third-party intellectual property, (3) costs to become a signatory under the tobacco MSA, and (4) license fees paid
to acquire a predicate cigarette brand. The amounts capitalized relate to intellectual property that the Company owns or to which
it has exclusive rights. The Company’s intellectual property capitalized costs are amortized using the straight-line method
over the remaining statutory life of the primary patent in each of the Company’s two primary patent families, which expire
in 2019 and 2028 (the assets’ estimated lives, respectively). Periodic maintenance or renewal fees are expensed as incurred. Annual
minimum license fees are charged to expense. License fees paid for third-party intellectual property are amortized on a straight-line
basis over the last to expire patents, which patent expiration dates range from 2028 through 2035. The Company believes costs
associated with becoming a signatory to the MSA and acquiring the predicate cigarette brand have an indefinite life and as such,
no amortization is taken. Total intangible assets at June 30, 2016 and December 31, 2015 consisted of the following:
|
|
June 30,
2016
|
|
|
December 31,
2015
|
|
Intangible assets, net
|
|
|
|
|
|
|
Patent and trademark costs
|
|
$
|
5,418,778
|
|
|
$
|
5,146,559
|
|
Less: accumulated amortization
|
|
|
1,805,765
|
|
|
|
1,603,893
|
|
Patent and trademark costs, net
|
|
|
3,613,013
|
|
|
|
3,542,666
|
|
|
|
|
|
|
|
|
|
|
License fees, net (see Note 11)
|
|
|
1,450,000
|
|
|
|
1,450,000
|
|
Less: accumulated amortization
|
|
|
179,557
|
|
|
|
130,546
|
|
License fees, net
|
|
|
1,270,443
|
|
|
|
1,319,454
|
|
|
|
|
|
|
|
|
|
|
MSA signatory costs
|
|
|
2,202,000
|
|
|
|
2,202,000
|
|
|
|
|
|
|
|
|
|
|
License fee for predicate cigarette brand
|
|
|
300,000
|
|
|
|
300,000
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
7,385,456
|
|
|
$
|
7,364,120
|
|
Amortization expense relating to the above
intangible assets for the three and six months ended June 30, 2016 amounted to $126,041 and $250,882, respectively ($109,702 and
$216,289 for the three and six months ended June 30, 2015, respectively).
The estimated annual average amortization
expense for the next five years is approximately $359,000 for patent costs and $98,000 for license fees.
Impairment of Long-Lived Assets
-
The Company reviews the carrying value of its amortizing long-lived assets whenever events or changes in circumstances indicate
that the historical cost-carrying value of an asset may no longer be recoverable. The Company assesses recoverability of the asset
by estimating the future undiscounted net cash flows expected to result from the asset, including eventual disposition. If the
estimated future undiscounted net cash flows are less than the carrying value of the asset, an impairment loss is recorded equal
to the difference between the asset’s carrying value and its fair value. There was no impairment loss recorded during the
six months ended June 30, 2016 or 2015.
Income Taxes
-
The
Company recognizes deferred tax assets and liabilities for any basis differences in its assets and liabilities between tax and
GAAP reporting, and for operating loss and credit carry-forwards.
In light of the Company’s history
of cumulative net operating losses and the uncertainty of their future utilization, the Company has established a valuation allowance
to fully offset its net deferred tax assets as of June 30, 2016 and December 31, 2015.
The Company’s federal and state
tax returns for the years ended December 31, 2012 to December 31, 2014 are currently open to audit under the statutes of limitations. There
were no pending audits as of June 30, 2016.
Stock Based Compensation
-
The Company uses a fair-value based method to determine compensation for all arrangements under which Company employees
and others receive shares or options to purchase common shares of the Company. Stock based compensation expense is recorded over
the requisite service period based on estimates of probability and time of achieving milestones and vesting. For accounting purposes,
the shares will be considered issued and outstanding upon vesting.
Revenue Recognition
-
The
Company recognizes revenue from product sales at the point the product is shipped to a customer and title has transferred. Revenue
from the sale of the Company’s products is recognized net of cash discounts, sales returns and allowances. Cigarette and
filtered cigar federal excise taxes and other regulatory fees in the approximate amount of $1,842,000 and $3,577,000 are included
in net sales and accounts receivable billed to customers for the three and six months ended June 30, 2016, respectively (approximately
$1,603,000 and $1,928,000 for the three and six months ended June 30, 2015), except on sales of
SPECTRUM
research
cigarettes, exported cigarettes and exported filtered cigars, to which such taxes do not apply. The Company recognizes revenue
from the sale of its
MAGIC
brand cigarettes in Europe when the cigarettes are sold by the European distributors to the
retailers and are sold net of cash discounts, sales returns and allowances, and all applicable taxes.
The Company was chosen to be a subcontractor
for a 5-year government contract between RTI International (“RTI”) and the National Institute on Drug Abuse (“NIDA”)
to supply NIDA with research cigarettes. These government research cigarettes are distributed under the Company’s mark
SPECTRUM
. In September 2015, the Company received a purchase order for approximately 5.0 million
SPECTRUM
research
cigarettes. Approximately 40% of the order was shipped in December 2015, resulting in the recognition of revenue in the amount
of $242,658 during the fourth quarter of 2015. The remainder of the order was shipped in January 2016 and generated revenue of
$329,321. There were no SPECTRUM cigarettes delivered during the three months ended June 30, 2016.
Derivatives
-
The Company
does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company evaluates all
of our financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives.
For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at
its fair market value and then is revalued at each reporting date, with changes in fair value reported in the Consolidated Statements
of Operations. The methodology for valuing our outstanding warrants classified as derivative instruments utilizes a lattice model
approach which includes probability weighted estimates of future events, including volatility of our common stock. The classification
of derivative instruments, including whether such instruments should be recorded as liabilities or equity, is evaluated at the
end of each reporting period. Derivative instrument liabilities are classified on the balance sheet as current or non-current
based on whether or not net-cash settlement of the derivative instrument could be required within twelve months of the balance
sheet date.
Research and Development
-
Research and development costs are expensed as incurred.
Advertising
- The Company expenses advertising costs as incurred. Advertising expense was approximately $27,000 and $235,000 for the
three and six months ended June 30, 2016, respectively ($64,000 and $115,000 for the three and six months ended June 30,
2015, respectively).
Loss Per Common Share
-
Basic loss per common share is computed using the weighted-average number of common shares outstanding. Diluted loss per
share is computed assuming conversion of all potentially dilutive securities. Potential common shares outstanding are excluded
from the computation if their effect is anti-dilutive.
Commitment and Contingency Accounting
-
The Company evaluates each commitment and/or contingency in accordance with the accounting standards, which state that
if the item is more likely than not to become a direct liability, then the Company will record the liability in the financial
statements. If not, the Company will disclose any material commitments or contingencies that may arise.
Use of Estimates
-
The preparation
of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates
and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities
at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results
could differ from those estimates.
Fair
Value of Financial Instruments
-
Financial instruments include cash, receivables,
accounts payable, accrued expenses, accrued severance, note payable and warrant liability. Other than warrant liability,
fair value is assumed to approximate carrying values for these financial instruments, since they are short term in nature,
they are receivable or payable on demand, or had stated interest rates that approximate the interest rates available to
the Company as of the reporting date. The determination of the fair value of the warrant liability includes
unobservable inputs and is therefore categorized as a Level 3 measurement, as further discussed in Note 10.
Equity Investments -
The
Company accounts for investments in equity securities of other entities under the equity method of accounting if the Company’s
investment in the voting stock is greater than or equal to 20% and less than a majority, and the Company has the ability to have
significant influence over the operating and financial policies of the investee.
Accounting
Pronouncements -
In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU 2014-09,
“Revenue from Contracts with Customers,” which supersedes nearly all existing revenue recognition guidance under
GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers
in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU
2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be
required within the revenue recognition process than are required under existing GAAP. The revised effective date for the ASU
is for annual periods beginning after December 15, 2017, and interim periods therein, using either of the following
transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting
period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of
initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). In August
2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers (Topic 606) - Deferral of the Effective Date, which
deferred the effective date of ASU 2014-09 to annual reporting periods beginning after December 15, 2017, with earlier
application permitted as of annual reporting periods beginning after December 15, 2016. In March 2016, the FASB issued ASU
No. 2016-08, Revenue from Contracts with Customers (Topic 606) - Principal versus Agent Considerations, to clarify
the implementation guidance on principal versus agent. In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts
with Customers (Topic 606) - Identifying Performance Obligations and Licensing, which clarifies the identifying performance
obligations and licensing implementation guidance. The Company is currently evaluating the impact of the pending adoption of
these ASU’s on its consolidated financial statements and has not yet determined the method by which it will adopt the
standard.
In August 2014, the FASB issued ASU 2014-15,
“Presentation of Financial Statements - Going Concern,” which provides guidance on determining when and how to disclose
going-concern uncertainties in the financial statements. The new standard requires management to perform interim and annual assessments
of an entity’s ability to continue as a going concern within one year of the date the financial statements are issued. An
entity will be required to provide certain disclosures if conditions of events raise substantial doubt about the entity’s
ability to continue as a going concern. The ASU applies to all entities and is effective for annual periods ending after December
15, 2016, and interim periods thereafter, with early adoption permitted. We are currently evaluating the impact of the adoption
of ASU 2014-15 on our consolidated financial statements and have not yet determined when we will adopt the standard.
In February 2016, the FASB issued ASU
2016-02, “Leases,” which supersedes existing lease guidance under GAAP. Under the new guidance, lessees will be required
to recognize leases as right of use assets and liabilities for leases with lease terms of more than twelve months. The guidance
will apply for both finance and operating leases. The effective date for the ASU is for annual periods beginning after December
15, 2018 and interim periods therein. The Company is currently evaluating the impact of the ASU on its consolidated financial
statements.
NOTE 2. - FEBRUARY 2016 REGISTERED DIRECT OFFERING
On February 5, 2016, the Company closed
a registered direct offering of common stock and warrants consisting of 5,000,000 shares of the Company’s common stock and
warrants to purchase 2,500,000 shares of the Company’s common stock at an exercise price of $1.21 per share. The warrants
were exercisable for a period of sixty-six (66) months after issuance, were not exercisable for a period of six months immediately
following the issuance and had a fair value of approximately $1,940,000 at issuance. The common stock and warrants were sold for
$1.10 per unit, resulting in net proceeds to the Company in the amount of $5,091,791, after deducting expenses associated with
the transaction (see Note 14 – Subsequent Events for additional information).
NOTE 3. - JUNE 2015 REGISTERED DIRECT OFFERING
On June 2, 2015, the Company closed a
registered direct offering of common stock and warrants consisting of 6,000,000 shares of the Company’s common stock and
warrants to purchase 3,000,000 shares of the Company’s common stock at an exercise price of $1.25 per share. The warrants
were exercisable for a period of sixty-six (66) months after issuance, were not exercisable for a period of six months immediately
following the issuance and had a fair value of approximately $2,067,000 at issuance. The common stock and warrants were sold for
$1.00 per unit, resulting in net proceeds to the Company in the amount of $5,576,083, after deducting expenses associated with
the transaction (see Note 14 – Subsequent Events for additional information).
NOTE 4. - JOINT VENTURE, CONSULTING
AGREEMENT AND ASSOCIATED WARRANTS
On June 22, 2015, the Company terminated
its joint venture arrangement with Crede CG III, Ltd. (“Crede”) and a third-party due to non-performance and other
breaches of the arrangement by Crede and its principals. The Company also notified Crede that the Company reserved and did not
waive, any rights that the Company may have to assert any and all claims that it may have against Crede, its employees, agents,
representatives or affiliates thereof, which are allowable by law or in equity, including claims for breach of the warrant agreements
entered into with Crede.
The six-month Consulting Agreement (the
“Consulting Agreement”), entered into with Crede on September 29, 2014, expired on March 29, 2015. The value of the
warrants issued in conjunction with the Consulting Agreement in the aggregate amount of $4,070,000 and initially recorded as prepaid
consulting fees have been fully amortized. The amortization of the prepaid consulting fees amounted to $1,978,785 for the three
months ended March 31, 2015, and are included in General and administrative expenses in the Company’s Consolidated Statements
of Operations. There was no amortization of prepaid consulting fees for the six months ended June 30, 2016.
Four tranches of warrants were
issued to Crede in conjunction with the Consulting Agreement as follows: Tranche 1A warrant to purchase 1,250,000 shares of Company
common stocks, Tranche IB warrant to purchase 1,000,000 shares of Company common stock, Tranche 2 warrant to purchase 1,000,000
shares of Company common stock and Tranche 3 warrant to purchase 1,000,000 shares of Company common stock. The Tranche 1A warrant
contained an exchange rights clause that required derivative liability treatment under FASB ASC 480 - “Distinguishing Liabilities
from Equity.” The Company valued the derivative liability associated with the Tranche 1A warrant at inception at $2,810,000
and the liability was recorded on the Company’s Consolidated Balance Sheets in Warrant liability. In March 2016, the Company
provided notice to Crede that Crede repeatedly breached the activity restrictions contained in the warrants and because the terms
of the warrant provide that the availability of the exchange feature was subject to compliance with such activity restrictions,
the exchange rights clause contained in the Tranche 1A warrant was no longer available and was thereafter void (although the remaining
amount of shares underlying the warrant without the exchange feature remained fully exercisable at $3.36 per share through the
warrant expiration date of September 29, 2016). Accordingly, the Company reclassified the warrant liability associated with the
Tranche 1A warrant to Capital in excess of par on its Consolidated Balance Sheets during March 2016.
The Tranche 2 and Tranche 3 warrants were
not exercisable unless and until certain revenue milestones were attained, as defined in the prior joint venture agreement between
Crede and the Company. As stated above, the Company terminated the joint venture agreement on June 22, 2015. Accordingly, such
revenue milestones will never be satisfied and the Tranche 2 and Tranche 3 warrants will never be exercisable.
NOTE 5. - MANUFACTURING FACILITY
The Company’s manufacturing operations
at its North Carolina factory were not at full production capacity during the six months ended June 30, 2016, but the Company
continued manufacturing a third-party MSA cigarette brand, filtered cigars on a contract basis, and the Company’s own proprietary
cigarette brand,
RED SUN
. Raw material component costs, direct manufacturing costs, and an overhead allocation are included
in the Cost of goods sold and finished goods inventory. General and administrative expenses of the factory amounted to $146,669
and $281,936 for the three and six months ended June 30, 2016, respectively ($152,601 and $284,119 for the three and six months
ended June 30, 2015, respectively).
NOTE 6. - MACHINERY AND EQUIPMENT
Machinery and equipment at June 30, 2016
and December 31, 2015 consisted of the following:
|
|
June 30,
|
|
|
December 31,
|
|
|
|
2016
|
|
|
2015
|
|
Cigarette manufacturing equipment
|
|
$
|
3,016,246
|
|
|
$
|
3,016,246
|
|
Office furniture, fixtures and equipment
|
|
|
96,882
|
|
|
|
95,361
|
|
Laboratory equipment
|
|
|
19,076
|
|
|
|
-
|
|
|
|
|
3,132,204
|
|
|
|
3,111,607
|
|
Less: accumulated depreciation
|
|
|
717,478
|
|
|
|
555,814
|
|
|
|
|
|
|
|
|
|
|
Machinery and equipment, net
|
|
$
|
2,414,726
|
|
|
$
|
2,555,793
|
|
Depreciation expense was $81,067 and $161,664
for the three and six months ended June 30, 2016, respectively ($78,630 and $157,440 for the three and six months ended June 30,
2015, respectively).
NOTE 7. - EQUITY INVESTMENT
On April 11, 2014, the Company, through
its wholly-owned subsidiary, Botanical Genetics, entered into an investment agreement (the “Agreement”) with Anandia
Laboratories, Inc., a Canadian plant biotechnology company (“Anandia”). The Agreement provided for the Company to
make an initial investment of $250,000 in Anandia in return for (i) a ten percent (10%) equity interest in Anandia, and (ii) certain
rights granted to the Company for four patent families (the “Intellectual Property”). The $250,000 investment was
made on April 14, 2014. On September 15, 2014, certain milestones were achieved triggering an additional cash investment in Anandia
in the amount of $450,000 in return for (i) an additional fifteen percent (15%) equity interest in Anandia, and (ii) a worldwide
sublicense agreement to the Intellectual Property, including exclusive rights within the U.S. In addition, the Company issued
150,000 unregistered shares of the Company’s common stock to Anandia with a value on the day of issuance of September 15,
2014 in the amount of $394,500, and on March 31, 2015, the Company issued to Anandia an additional 377,906 unregistered shares
of the Company’s common stock with an aggregate market value of $325,000 at the time of the issuance in accordance with
the Agreement.
The Company uses the equity method
of accounting to record its 25% ownership interest in Anandia. As of June 30, 2016 and December 31, 2015, the Company’s
equity investment balance in Anandia was $1,080,580 and $1,222,651, respectively, and is classified within Other assets on
the accompanying Consolidated Balance Sheets. As of December 31, 2014, the carrying value of our investment in Anandia was
approximately $1,199,000 in excess of our share of the book value of the net assets of Anandia, with such difference being
attributable to intangible assets. This intangible asset is being amortized over the expected benefit period and this
amortization expense of $14,412 and $28,824 for each of the three and six months ended June 30, 2016 and 2015, respectively,
has been included in the Loss on equity investment in the accompanying Consolidated Statements of Operations. In addition,
the Company has recorded an equity loss of $40,427 and $113,247 for the three and six months ended June 30, 2016,
respectively, representing 25% of Anandia’s net losses, resulting in a total loss on equity investment of $54,839 and
$142,071 for the three and six months ended June 30, 2016, respectively, (the Company recorded an equity loss of $26,422 and
$62,991 for the three and six months ended June 30, 2015, resulting in a total loss on equity investment of $40,834 and
$91,815 for the three and six months ended June 30, 2015, respectively).
NOTE 8. - NOTES PAYABLE AND PATENT
ACQUISITION
On
December 22, 2014, the Company entered into a Purchase Agreement (the “Purchase Agreement”) with the National
Research Council of Canada (“NRC”) to acquire certain patent rights that the Company had previously licensed from
NRC under a license agreement between the parties. The Purchase Agreement provided for payment by the Company to NRC for the
NRC patent rights a total amount of $1,213,000, of which $213,000 was paid in cash at the closing on December 23, 2014, and
with the remaining $1,000,000 balance paid in three equal installments of $333,333 in December of 2015, 2016 and 2017,
respectively, with no interest on the installment payments unless the Company defaults on any such installment payment. As
such, the Company computed the present value of the note payable using the Company’s incremental borrowing rate. The
resulting present value of the note payable amounted to $925,730 at December 31, 2014. After the required installment payment
of $333,333 made by the Company to NRC on December 22, 2015 and the accretion of interest, the remaining present value of the
note payable amounts to $628,816; with $320,878 and $307,938 recorded as the current and long-term portion of the note
payable, respectively, at June 30, 2016 ($616,520; with $308,582 and $307,938 as the current and long-term portion of the
note payable, respectively, at December 31, 2015). The cost of the acquired patents in the amount of $1,138,730 (cash
of $213,000 plus the original discounted notes payable in the amount of $925,730) are included in Intangible assets, net on
the Company’s Consolidated Balance Sheets. All previous license agreements between NRC and the Company were terminated
as a condition of the Purchase Agreement. NRC has a security interest in these patent rights acquired by the Company from NRC
until the note payable has been satisfied.
NOTE 9. - SEVERANCE LIABILITY
The Company recorded an accrual for severance
during the fourth quarter of 2014 in the initial amount of $624,320 in accordance with FASB ASC 712. The severance accrual relates
to the October 25, 2014 termination of Joseph Pandolfino, the Company’s former Chairman of the Board and Chief Executive
Officer. The prior Employment Agreement with Mr. Pandolfino provided that in certain circumstances Mr. Pandolfino would receive
severance payments in the gross amount of $18,750 per month, subject to customary withholdings, over a term of 36 months. Amounts
owed to Mr. Pandolfino have been discounted using the Company’s incremental borrowing rate, resulting in current and long-term
liabilities of $212,012 and $412,308, respectively, at December 31, 2014. Due to alleged breaches of the Employment Agreement
by Mr. Pandolfino, payments were suspended by the Company on February 13, 2015. Resulting litigation between Mr. Pandolfino and
the Company was settled on November 6, 2015, and pursuant to the settlement agreement Mr. Pandolfino’s severance benefits
were reinstated, including a catch-up payment through the date of the settlement. As a result of the severance benefit payments
made through the second quarter of 2016, the discounted current and long-term balance of the severance liability amounted to $225,117
and $90,101, respectively, at June 30, 2016 ($220,661 and $199,658, respectively, at December 31, 2015).
NOTE 10. - WARRANTS FOR COMMON STOCK
At June 30, 2016, the Company had outstanding
warrants to purchase 10,236,621 shares of common stock of the Company, of which only 92,632 warrants contain an anti-dilution
feature.
The Crede Tranche 2 and Tranche 3 warrants are excluded from the outstanding warrant total of 10,236,621 (see
Note 4 for additional discussion).
On January 25, 2016 warrants to purchase
67,042 shares of common stock were exercised, primarily on a cashless basis, resulting in the issuance of 2,618 shares of the
Company’s common stock. On January 25, 2016, warrants to purchase 6,831,115 shares of common stock expired without being
exercised.
Pursuant to the registered
direct offering that closed on February 5, 2016, and discussed in Note 2, the Company issued warrants to purchase 2,500,000 shares
of common stock with an exercise price of $1.21 per share. These warrants had a term of sixty-six (66) months, were not exercisable
for six months immediately following the date of issuance, did not contain an anti-dilution feature, and had a fair value of approximately
$1,940,000 at issuance (see Note 14 – Subsequent Events for additional information).
Pursuant to the registered direct offering
that closed on June 2, 2015, and discussed in Note 3, the Company issued warrants to purchase 3,000,000 shares of common stock
with an exercise price of $1.25 per share. These warrants had a term of sixty-six (66) months, were not exercisable for six months
immediately following the date of issuance, did not contain an anti-dilution feature, and had a fair value of approximately $2,067,000
at issuance (see Note 14 – Subsequent Events for additional information).
Outstanding warrants at June 30, 2016
consisted of the following:
|
|
Number of
|
|
|
Exercise
|
|
|
|
Warrant Description
|
|
Warrants
|
|
|
Price
|
|
|
Expiration
|
|
|
|
|
|
|
|
|
|
December 2011 convertible NP warrants
|
|
|
172,730
|
|
|
$
|
1.1984
|
|
|
February 8, 2017
|
December 2011 convertible NP warrants
|
|
|
802,215
|
|
|
$
|
1.3816
|
|
|
February 6, 2018
|
May 2012 PPO warrants
|
|
|
401,700
|
|
|
$
|
0.6000
|
|
|
May 15, 2017
|
November 2012 PPO warrants
|
|
|
925,100
|
|
|
$
|
0.6000
|
|
|
November 9, 2017
|
August 2012 convertible NP warrants
(1)
|
|
|
92,632
|
|
|
$
|
0.9520
|
|
|
August 8, 2018
|
August 2012 convertible NP warrants
|
|
|
92,244
|
|
|
$
|
0.9060
|
|
|
August 8, 2018
|
Crede Tranche 1A warrants
|
|
|
1,250,000
|
|
|
$
|
3.3600
|
|
|
September 29, 2016
|
Crede Tranche 1B warrants
|
|
|
1,000,000
|
|
|
$
|
2.5951
|
|
|
September 29, 2016
|
June 2015 registered direct offering warrants
|
|
|
3,000,000
|
|
|
$
|
1.2500
|
|
|
December 2, 2020
(5)
|
February 2016 registered direct offering warrants
|
|
|
2,500,000
|
|
|
$
|
1.2100
|
|
|
August 5, 2021
(5)
|
|
|
|
|
|
|
|
|
|
|
|
Total warrants outstanding
(2),(3),(4)
|
|
|
10,236,621
|
|
|
|
|
|
|
|
(1)
|
Includes anti-dilution features.
|
(2)
|
Includes warrants to purchase 533,000 shares of common stock (5.2%) held by officers and directors
that have had the anti-dilution feature removed.
|
(3)
|
Includes warrants to purchase 312,730 shares of common stock (3.1%) held by a former officer
and director that have had the anti-dilution feature removed.
|
(4)
|
Excludes the Crede Tranche 2 and Tranche 3 warrants to purchase 2,000,000 shares of common
stock because the warrants will never be exercisable (see Note 4 for additional discussion).
|
(5)
|
The warrants were terminated on July 27,
2016 (see Note 14 - Subsequent Events for additional information).
|
The Company estimates the value of warrant
liability upon issuance of the warrants and at each balance sheet date using the binomial lattice model to allocate total enterprise
value to the warrants and other securities in the Company’s capital structure. Volatility was estimated based on historical
observed equity volatilities and implied (forward) or expected volatilities for a sample group of guideline companies and consideration
of recent market trends.
As a result of the previously exercisable
exchange rights contained in the Tranche 1A warrants, the financial instrument was previously considered a liability in accordance
with FASB Accounting Standards Codification Topic 480 - “Distinguishing Liabilities from Equity” (“ASC 480”).
More specifically, ASC 480 requires a financial instrument to be classified as a liability if such financial instrument contains
a conditional obligation that the issuer must or may settle by issuing a variable number of its equity securities if, at inception,
the monetary value of the obligation is based on a known fixed monetary amount. As a result of the actions by Crede that caused
the exchange rights feature to be voided, the Company reclassified the Tranche 1A warrant liability to Capital in excess of par.
The following table is a roll-forward
summary of the warrant liability:
Fair value at December 31, 2013
|
|
$
|
3,779,522
|
|
Reclassification of warrant liability to equity resulting from Warrant Amendments - Q1 2014
|
|
|
(7,367,915
|
)
|
Cost of inducement from Warrant Amendments - Q1 2014
|
|
|
144,548
|
|
Fair value of warrant liability resulting from issuance of Crede Tranche 1A Warrants - Q3 2014
|
|
|
2,810,000
|
|
Loss as a result of change in fair value
|
|
|
3,676,691
|
|
Fair value at December 31, 2014
|
|
$
|
3,042,846
|
|
Gain as a result of change in fair value
|
|
|
(144,550
|
)
|
Fair value at December 31, 2015
|
|
$
|
2,898,296
|
|
Reclassification of warrant liability to capital in excess of par
|
|
|
(2,810,000
|
)
|
Gain as a result of change in fair value
|
|
|
(61,597
|
)
|
Fair value at June 30, 2016
|
|
$
|
26,699
|
|
The aggregate net (loss) gain as a result
of the Company’s warrant liability for the three and six months ended June 30, 2016 amounted to ($9,468) and $61,597, respectively
(the aggregate net gain for the three and six months ended June 30, 2015 amounted to $112,620 and $171,833, respectively), which
are included in Other income (expense) under Warrant liability (loss) gain - net in the accompanying Consolidated Statements of
Operations.
FASB ASC 820 - “Fair Value Measurements
and Disclosures” establishes a valuation hierarchy for disclosure of the inputs to valuation used to measure fair value.
This hierarchy prioritizes the inputs into three broad levels as follows:
·
|
Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities;
|
|
|
·
|
Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs
that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially
the full term of the financial instrument; and
|
|
|
·
|
Level 3 inputs are unobservable inputs based on the Company’s own assumptions used to
measure assets and liabilities at fair value.
|
A financial asset’s or a financial
liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the
fair value measurement. The warrant liability is measured at fair value using certain estimated factors such as volatility and
probability which are classified within Level 3 of the valuation hierarchy. Significant unobservable inputs that are used in the
fair value measurement of the Company’s derivative warrant liabilities include volatility. Significant increases (decreases)
in the volatility input would result in a significantly higher (lower) fair value measurement.
The following table summarizes the Company’s
warrant activity since December 31, 2013:
|
|
Number of
Warrants
|
|
|
|
|
|
Warrants outstanding at December 31, 2013
|
|
|
10,653,469
|
|
Warrants issued in conjunction with consulting agreement
|
|
|
4,250,000
|
|
Warrants exercised during 2014
|
|
|
(1,247,443
|
)
|
Additional warrants due to anti-dilution provisions
|
|
|
18,383
|
|
Warrants outstanding at December 31, 2014
|
|
|
13,674,409
|
|
Warrants issued in conjunction with registered direct offering
|
|
|
3,000,000
|
|
Warrants exercised during 2015
|
|
|
(40,000
|
)
|
Additional warrants due to anti-dilution provisions
|
|
|
369
|
|
Warrants outstanding at December 31, 2015
|
|
|
16,634,778
|
|
Warrants issued in conjunction with registered direct offering
|
|
|
2,500,000
|
|
Unexercisable warrants
(1)
|
|
|
(2,000,000
|
)
|
Warrants exercised during January 2016
|
|
|
(67,042
|
)
|
Warrants expired during January 2016
|
|
|
(6,831,115
|
)
|
Warrants outstanding at June 30, 2016
|
|
|
10,236,621
|
|
|
|
|
|
|
Composition of outstanding warrants:
|
|
|
|
|
Warrants containing anti-dilution feature
|
|
|
92,632
|
|
Warrants without anti-dilution feature
|
|
|
10,143,989
|
|
|
|
|
10,236,621
|
|
(1)
|
Crede Tranche 2 Warrants and Tranche 3 Warrants are not exercisable (see Note
4 for additional discussion).
|
NOTE 11. - COMMITMENTS AND CONTINGENCIES
License Agreements -
Under
its exclusive worldwide license agreement with North Carolina State University (“NCSU”), the Company is required to
pay minimum annual royalty payments, which are credited against running royalties on sales of licensed products. The minimum annual
royalty for 2015 was $75,000 and in 2016 the minimum annual royalty increased to $225,000. The license agreement continues through
the life of the last-to-expire patent, which is expected to be 2022. The license agreement also requires a milestone payment of
$150,000 upon FDA approval or clearance of a product that uses the NCSU licensed technology. The Company is also responsible for
reimbursing NCSU for actual third-party patent costs incurred. These costs vary from year to year and the Company has certain
rights to direct the activities that result in these costs. During the three and six months ended June 30, 2016, the aggregate
costs incurred related to capitalized patent costs and patent maintenance expense amounted to $10,016 and $13,996, respectively
($6,278 and $23,606 during the three and six months ended June 30, 2015, respectively).
On December 8, 2015, the Company entered
into an additional license agreement (the “License”) with NCSU. Under the terms of the License, the Company paid NCSU
a non-refundable, non-creditable lump sum license fee of $150,000. Additionally, the License calls for the Company to pay NCSU
a non-refundable, non-creditable minimum annual royalties beginning on December 31, 2018 in the amount of $10,000. The minimum
annual royalty payment increases to $15,000 in 2019, $25,000 in 2020 and 2021, and $50,000 per year thereafter for the remaining
term of the License. The Company is also responsible for reimbursing NCSU for actual third-party patent costs incurred. During
the three and six months ended June 30, 2016, the aggregate costs incurred related to capitalized patent costs and patent maintenance
expense amounted to $0 and $6,075, respectively ($0 for the three and six months ended June 30, 2015). This License continues
through the life of the last-to-expire patent, expected to be in 2036.
On February 10, 2014, the Company entered
into a sponsored research and development agreement (the “Agreement”) with NCSU. Under the terms of the Agreement,
the Company paid NCSU $162,408 over the two-year term of the Agreement, which grants certain licensed rights to the Company. The
Company has extended the Agreement through January 31, 2017 at an additional cost of $85,681.
All payments made under the above referenced
license agreements and the sponsored research and development agreement are initially recorded as a Prepaid expense on the Company’s
Consolidated Balance Sheets and subsequently expensed on a straight-line basis over the applicable period and included in Research
and development costs on the Company’s Consolidated Statements of Operations. The amounts expensed during the three and
six months ended June 30, 2016 were $115,170 and $229,967, respectively ($39,051 and $78,102 for the three and six months
ended June 30, 2015, respectively).
On August 22, 2014, the Company entered
into a Commercial License Agreement with Precision PlantSciences, Inc. (the “Precision License”). The Precision License
grants the Company a non-exclusive, but fully paid up right and license to use technology and materials owned by Precision PlantSciences
for a license fee of $1,250,000. An initial cash payment of $725,000 was made upon execution of the Precision License with an
unconditional obligation to pay the remaining $525,000 in $25,000 increments as materials are provided to the Company. The remaining
$525,000 was paid during December 2014. The Precision License continues through the life of the last-to-expire patent, which is
expected to be in 2028.
On August 27, 2014, the Company entered
into an additional exclusive License Agreement (the “License Agreement”) with NCSU. Under the License Agreement, the
Company paid NCSU a non-refundable, non-creditable lump sum license fee of $125,000. Additionally, the License Agreement calls
for the Company to pay NCSU three non-refundable, non-creditable license maintenance fees in the amount of $15,000 per annum in
each of December 2015, 2016 and 2017. Beginning in calendar year 2018, the Company is obligated to pay to NCSU an annual minimum
royalty fee of $20,000 in 2018, $30,000 in 2019, and $50,000 per year thereafter for the remaining term of the License Agreement.
The Company is also responsible for reimbursing NCSU for actual third-party patent costs incurred. During the three and six months
ended June 30, 2016, the aggregated costs incurred related to capitalized patent costs and patent maintenance expense amounted
to $5,983 and $33,939, respectively, ($522 and $4,204 for the three and six months ended June 30, 2015, respectively). The License
Agreement continues through the life of the last-to-expire patent, which is expected to be in 2034.
On September 15, 2014, the Company entered
into a Sublicense Agreement with Anandia Laboratories, Inc. (the “Anandia Sublicense”). Under the terms of the Anandia
Sublicense, the Company was granted an exclusive sublicense in the United States and a co-exclusive sublicense in the remainder
of the world, excluding Canada, to the licensed Intellectual Property (more fully discussed in Note 7). The Anandia Sublicense
calls for an up-front fee of $75,000, an annual license fee of $10,000, the payment of patent filing and maintenance costs, and
a running royalties on future net sales. The Anandia Sublicense continues through the life of the last-to-expire patent, which
is expected to be in 2035.
The Precision License, the License
Agreement with NCSU and the Anandia Sublicense are included in Intangible assets, net in the Company’s Consolidated
Balance Sheets and the applicable license fees will be amortized over the term of the agreements based on their
last-to-expire patent date. Amortization during the three and six months ended June 30, 2016 amounted to $24,505 and $49,011,
respectively, ($24,506 and $49,011 for the three and six months ended June 30, 2015, respectively) and was included in accumulated
amortization on the Company’s Consolidated Statements of Operations.
On September 28, 2015, the Company’s
wholly-owned subsidiary, Botanical Genetics, entered into a Sponsored Research Agreement (the “Agreement”) with Anandia
Laboratories Inc. (“Anandia”). Pursuant to the Agreement, Anandia will conduct research on behalf of the Company relating
to the cannabis plant. The Agreement has an initial term of twelve (12) months from the date of the Agreement and can be extended
at the sole option of the Company for two (2) additional periods of twelve (12) months each. The Company will pay Anandia $379,800
over the initial term of the Agreement, of which $295,600 has been paid through June 30, 2016. A final payment in the amount of
$84,200 is due in the third quarter of 2016. During the three and six months ended June 30, 2016 expenses related to the Agreement
amounted to $84,200 and $179,200, respectively ($0 for the three and six months ended June 30, 2015), and are included in Research
and development costs on the Company’s Consolidated Statements of Operations. Under the terms of the Agreement, the Company
will have co-exclusive worldwide rights with Anandia to all the intellectual property resulting from the sponsored research between
the Company and Anandia. The party that commercializes such intellectual property in the future will pay royalties in varying
amounts to the other party, with the amount of such royalties being dependent upon the type of products that are commercialized
in the future. If either party sublicenses such intellectual property to a third-party, then the Company and Anandia will share
equally in such sublicensing consideration.
Lease Agreements
- The Company
leases a manufacturing facility and warehouse located in North Carolina on a triple net lease basis. The lease commenced on January
14, 2014, and had an initial term of twelve (12) months. The lease contains four (4) additional extensions; with one lease extension
being for an additional one (1) year and with the other three (3) lease extensions each being for an additional two (2) years
in duration, exercisable at the option of the Company. The Company is currently in the one-year lease extension term that will
expire on October 31, 2016. The lease expense for the three and six months ended June 30, 2016 amounted to $36,131 and $72,262,
respectively ($30,750 and $61,500, for the three and six months ended June 30, 2015, respectively). The future minimum lease
payments if the Company exercises each of the additional extensions are approximately as follows:
Year ended December 31, 2016 -
|
|
$
|
74,000
|
|
Year ended December 31, 2017 -
|
|
$
|
156,000
|
|
Year ended December 31, 2018 -
|
|
$
|
169,000
|
|
Year ended December 31, 2019 -
|
|
$
|
169,000
|
|
Year ended December 31, 2020 -
|
|
$
|
169,000
|
|
Year ended December 31, 2021 -
|
|
$
|
141,000
|
|
The Company has a lease for its office
space in Clarence, New York that expires on August 31, 2016, with the Company having the option to extend this lease for an additional
one-year renewal period expiring on August 31, 2017. Future minimum lease payments for the years ended December 31, 2016 and 2017
are approximately $23,000 and $31,000, respectively, if the Company exercises the optional renewal period.
On November 1, 2015, the Company entered
into a one-year lease for 25,000 square feet of warehouse space in North Carolina to store the Company’s proprietary tobacco
leaf. The lease calls for a monthly lease payment of $3,750 and contains a three-year renewal option after the initial one-year
term. Future minimum lease payments for the years ended December 31, 2016, 2017, 2018 and 2019 are $22,500, $45,000, $45,000 and
$37,500, respectively, if the Company exercises the optional renewal period.
On May 1, 2016, the Company entered into
a sublease for laboratory space in Buffalo, New York. The sublease calls for a monthly payment of $1,471, expires on April 30,
2017 and contains an option to extend the lease for a period of one year through April 30, 2018. Future minimum sublease payments
for the years ended December 31, 2016, 2017 and 2018 are approximately $8,800, $18,000 and $6,000 respectively, if the Company
exercises the optional renewal period.
Litigation
- In accordance
with applicable accounting guidance, the Company establishes an accrued liability for litigation and regulatory matters when those
matters present loss contingencies that are both probable and estimable. In such cases, there may be an exposure to loss in excess
of any amounts accrued. When a loss contingency is not both probable and estimable, the Company does not establish an accrued
liability. As a litigation or regulatory matter develops, the Company, in conjunction with any outside counsel handling the matter,
evaluates on an ongoing basis whether such matter presents a loss contingency that is probable and estimable. If, at the time
of evaluation, the loss contingency related to a litigation or regulatory matter is not both probable and estimable, the matter
will continue to be monitored for further developments that would make such loss contingency both probable and estimable. When
a loss contingency related to a litigation or regulatory matter is deemed to be both probable and estimable, the Company will
establish an accrued liability with respect to such loss contingency and record a corresponding amount of litigation-related expense.
The Company will then continue to monitor the matter for further developments that could affect the amount of any such accrued
liability.
On
April 26, 2016, Crede CG III, LTD. (“Crede”) filed a complaint against the Company in the United States District
Court for the Southern District of New York (the “SDNY Court”) entitled
Crede CG III, LTD. v. 22nd Century
Group, Inc
. On May 19, 2016, Crede filed an Amended Complaint that includes seven counts, alleging among other things,
that the Company allegedly breached and/or interfered with certain agreements entered into with Crede, including the joint
venture agreement relating to efforts to sell the Company’s proprietary tobacco into China, the Tranche 1A Warrant and
the prior securities purchase agreement with Crede. The Amended Complaint seeks money damages, to rescind the stock purchase
agreement, to obtain declaratory and injunctive relief to require the Company to issue to Crede 2,077,555 shares of the
Company’s common stock under the exchange provision of the Tranche 1A Warrant, and entry of an injunction prohibiting
the Company from selling tobacco into China without the joint venture’s involvement. The Amended Complaint also seeks
attorney’s fees and such other relief as the Court may deem just and proper. We believe that the claims are frivolous,
meritless and that the Company has substantial legal and factual defenses to the claims. The Company has defended and intends
to continue to defend against these claims vigorously, and has filed letter motions for the dismissal of the claims and for
the transfer of certain of the claims to the United States District Court for the Western District of New York
(the “WDNY Court”). The Company also intends to file counterclaims if the case continues.
On May 19, 2016, Crede filed a motion for
preliminary injunction, asking the SDNY Court to require the Company to issue 2,077,555 shares of its common stock to Crede under
the exchange provision of the Tranche 1A Warrant. After conducting an evidentiary hearing on this motion on June 14, 2016, the
SDNY Court denied Crede’s motion and held, among other things, that Crede did not prove the potential for irreparable harm
or a likelihood of success on its claim for such 2,077,555 shares under the Tranche 1A Warrant, and that there was a likelihood
that Crede had violated the activity restrictions of the Tranche 1A Warrant, which would bar Crede’s claim for such shares
from the Company.
Following such ruling, the SDNY Court
directed the parties to file briefs on the pending letter motion to transfer certain claims to the WDNY Court. On July 11, 2016,
the Company filed its formal motion to sever the Crede lawsuit into two separate cases, with all claims relating to the Tranche
1A Warrant to stay in the SDNY Court, and with the claims relating to the China joint venture agreement and the securities purchase
agreement to be transferred to WDNY Court, where the Company’s headquarters is located. On July 29, 2016, Crede filed its
response to the Company’s motion and on August 5, 2016, the Company filed its reply to Crede’s response. We expect
the SDNY Court to conduct a telephonic hearing on the motion in August 2016.
NOTE 12. - EARNINGS PER COMMON SHARE
The following table sets forth the computation
of basic and diluted earnings per common share for the three month periods ended June 30, 2016 and 2015:
|
|
June 30,
|
|
|
June 30,
|
|
|
|
2016
|
|
|
2015
|
|
|
|
|
|
|
|
|
Net loss attributed to common shareholders
|
|
$
|
(2,902,354
|
)
|
|
$
|
(1,288,703
|
)
|
|
|
|
|
|
|
|
|
|
Denominator for basic earnings per share-weighted average
shares outstanding
|
|
|
76,024,064
|
|
|
|
66,616,739
|
|
|
|
|
|
|
|
|
|
|
Effect of dilutive securities:
|
|
|
|
|
|
|
|
|
Warrants, restricted stock and options outstanding
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
Denominator for diluted earnings
per common share-weighted average shares adjusted for dilutive securities
|
|
|
76,024,064
|
|
|
|
66,616,739
|
|
|
|
|
|
|
|
|
|
|
Loss per common share - basic and diluted
|
|
$
|
(0.04
|
)
|
|
$
|
(0.02
|
)
|
The following table sets forth the computation
of basic and diluted earnings per common share for the six month periods ended June 30, 2016 and 2015:
|
|
June 30,
|
|
|
June 30,
|
|
|
|
2016
|
|
|
2015
|
|
|
|
|
|
|
|
|
Net loss attributed to common shareholders
|
|
$
|
(6,154,806
|
)
|
|
$
|
(5,405,442
|
)
|
|
|
|
|
|
|
|
|
|
Denominator for basic earnings per share-weighted average
shares outstanding
|
|
|
75,027,606
|
|
|
|
65,408,908
|
|
|
|
|
|
|
|
|
|
|
Effect of dilutive securities:
|
|
|
|
|
|
|
|
|
Warrants, restricted stock and options outstanding
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
Denominator for diluted earnings
per common share-weighted average shares adjusted for dilutive securities
|
|
|
75,027,606
|
|
|
|
65,408,908
|
|
|
|
|
|
|
|
|
|
|
Loss per common share - basic and diluted
|
|
$
|
(0.08
|
)
|
|
$
|
(0.08
|
)
|
Securities outstanding that were excluded
from the computation because they would have been anti-dilutive are as follows:
|
|
June 30,
|
|
|
June 30,
|
|
|
|
2016
|
|
|
2015
|
|
Warrants
|
|
|
10,236,621
|
|
|
|
16,674,778
|
|
Restricted stock
|
|
|
-
|
|
|
|
100,000
|
|
Options
|
|
|
4,985,679
|
|
|
|
2,661,642
|
|
|
|
|
15,222,300
|
|
|
|
19,436,420
|
|
NOTE 13. - EQUITY BASED COMPENSATION
On October 21, 2010, the Company established
the 2010 Equity Incentive Plan (“EIP”) for officers, employees, directors, consultants and advisors to the Company
and its affiliates, which consisted of 4,250,000 shares of common stock. During the first quarter of 2014, the Company issued
restricted stock awards from the EIP for 850,000 restricted shares to employees and directors that vested on January 27, 2015.
All awards were valued at the closing price of the Company’s common stock on the measurement date of the award. No additional
awards are issuable under the EIP.
On April 12, 2014, the stockholders of
the Company approved the 22nd Century Group, Inc. 2014 Omnibus Incentive Plan (the “OIP”). The OIP allows for the
granting of equity and cash incentive awards to eligible individuals over the life of the OIP, including the issuance of up to
5,000,000 shares of the Company’s common stock pursuant to awards under the OIP. The OIP has a term of ten years and is
administered by the Compensation Committee of the Company’s Board of Directors to determine the various types of incentive
awards that may be granted to recipients under this plan and the number of shares of common stock to underlie each such award
under the OIP.
During the three and six months ended
June 30, 2016, the Company issued stock option awards from the OIP for 90,000 and 1,724,037, respectively, to eligible individuals
having vesting periods ranging from one to three years from the date of the award. During the three months ended June 30, 2015,
the Company issued 61,643 stock option awards from the OIP, and during the three months ended March 31, 2015, the Company issued
restricted stock and stock options from the OIP for 20,000 shares and 1,559,999 shares, respectively, to eligible individuals
having vesting periods ranging from six months to one year from the date of the awards. All stock option awards were valued using
the Black-Scholes option-pricing model on the date of the award, and all restricted stock awards were valued at the closing price
of the Company’s common stock on the NYSE MKT on the date of the award.
For
the three and six months ended June 30, 2016 the Company recorded compensation expense related to restricted stock and
stock option awards granted under the EIP and OIP of $212,222 and $472,216, respectively, ($331,773 and $685,860 for the
three and six months ended June 30, 2015, respectively). During the three and six months ended June 30, 2016, the Company
issued stock to third-party service providers in the amount of 10,000 and 15,811, respectively, and during the three months
ended June 30, 2016, the Company issued stock options in the amount of 100,000 shares to a third-party service provider. During the
three months ended March 31, 2015, the Company issued restricted stock and stock options to third-party service providers in
the amount of 189,196 and 100,000 shares, respectively. During the three months ended June 30, 2015, there were no issuances
of restricted stock or stock options to third-party service providers. The Company recorded equity based compensation expense
related to the third-party providers for the three and six months ended June 30, 2016 in the amount of $8,000 and
$30,873, respectively, ($25,885 and $134,218 for the three and six months ended June 30, 2015, respectively).
As of June 30, 2016, unrecognized compensation
expense related to non-vested restricted shares and stock options amounted to approximately $1,327,000, which is expected to be
recognized approximately as follows: $371,000, $362,000, $272,000 and $48,000 during 2016, 2017, 2018 and 2019, respectively.
Approximately $274,000 of the unrecognized compensation expense relates to previously issued stock options, with the vesting of
such stock options being based on the achievement of a certain milestone, and the attainment of such milestone cannot be determined
at this time.
The fair value of each option grant is
estimated on the date of grant using the Black-Scholes option-pricing model. The following assumptions were used for the six months
ended June 30, 2016 and 2015:
|
|
2016
|
|
|
2015
|
|
Risk-free interest rate (weighted average)
|
|
|
1.38
|
%
|
|
|
1.50
|
%
|
Expected dividend yield
|
|
|
0
|
%
|
|
|
0
|
%
|
Expected stock price volatility
|
|
|
90
|
%
|
|
|
90
|
%
|
Expected life of options (weighted average)
|
|
|
5.03 years
|
|
|
|
8.66 years
|
|
The Company estimated the expected volatility
based on data used by a peer group of public companies. The expected term was estimated using the contract life of the option.
The risk-free interest rate assumption was determined using yield of the equivalent U.S. Treasury bonds over the expected term.
The Company has never paid any cash dividends and does not anticipate paying any cash dividends in the foreseeable future. Therefore,
the Company assumed an expected dividend yield of zero.
A summary of all stock option activity
since December 31, 2013 is as follows:
|
|
Number of
Options
|
|
|
Weighted
Average
Exercise Price
|
|
|
Weighted
Average
Remaining
Contractual
Term
|
|
|
Aggregate
Intrinsic
Value
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding at December 31, 2013
|
|
|
660,000
|
|
|
$
|
0.74
|
|
|
|
|
|
|
|
|
|
Granted in 2014
|
|
|
300,000
|
|
|
$
|
2.61
|
|
|
|
|
|
|
|
|
|
Exercised in 2014
|
|
|
(70,000
|
)
|
|
$
|
0.69
|
|
|
|
|
|
|
|
|
|
Outstanding at December 31, 2014
|
|
|
890,000
|
|
|
$
|
1.38
|
|
|
|
|
|
|
|
|
|
Reinstated in 2015
|
|
|
50,000
|
|
|
$
|
0.69
|
|
|
|
|
|
|
|
|
|
Granted in 2015
|
|
|
2,221,642
|
|
|
$
|
1.00
|
|
|
|
|
|
|
|
|
|
Outstanding at December 31, 2015
|
|
|
3,161,642
|
|
|
$
|
1.10
|
|
|
|
|
|
|
|
|
|
Granted in 2016
|
|
|
1,824,037
|
|
|
$
|
0.94
|
|
|
|
|
|
|
|
|
|
Outstanding at June 30, 2016
|
|
|
4,985,679
|
|
|
$
|
1.04
|
|
|
|
7.7 years
|
|
|
$
|
92,450
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercisable at June 30, 2016
|
|
|
2,511,642
|
|
|
$
|
1.15
|
|
|
|
7.1 years
|
|
|
$
|
56,950
|
|
There were stock options granted during
the six months ended June 30, 2016 and 2015, to purchase a total of 1,824,037 shares and 1,721,642 shares, respectively. The weighted
average grant date fair value of options issued during six months ended June 30, 2016 was $0.64 ($0.59 for the six months ended
June 30, 2015). The total fair value of options that vested during the six months ended June 30, 2016 amounted to $1,138,910 ($206,500
for the six months ended June 30, 2015). No options were exercised during the six months ended June 30, 2016 and 2015.
NOTE 14. - SUBSEQUENT EVENTS
On July 27, 2016, the Company closed a registered direct offering of units, with each unit consisting
of one share of common stock and a warrant to purchase 1.141 shares of common stock. The purchase price per unit was $0.81 and
one institutional investor purchased $5.0 million of units, consisting of an aggregate of 6,172,840 shares of common stock and
warrants to purchase up to 7,043,211 shares of common stock. The warrants provide for an exercise price of $1.00 per share and
1,543,210 of the warrants are exercisable immediately and had a fair value of approximately $858,000 at issuance and 5,500,001
of the warrants are exercisable six months from the date of issuance and had a fair value of approximately $3,058,000 at issuance.
All of the warrants have a term of 5.5 years. The exercise price of the warrants will also be adjusted in the event of stock splits,
reverse stock splits and the like pursuant to their terms. The holder of the warrants will not have the right to exercise any portion
of the warrant if the holder, together with its affiliates, would beneficially own in excess of 4.99% of the number of shares of
the Company’s common stock (including securities convertible into common stock) outstanding immediately after the exercise;
provided, however, that the holder may increase or decrease this limitation at any time, although any increase shall not be effective
until the 61
st
day following the notice
of increase and the holder may not increase this limitation in excess of 9.99%. The Securities Purchase Agreement executed with
the investor provides that, subject to certain exceptions, for a period ending on the earlier of (i) 90 days after July 27, 2016
and (ii) the trading day following the day that the closing price of the Company’s common stock exceeds $1.15 per share for
ten consecutive trading days, neither the Company nor any of its subsidiaries will issue, enter into any agreement to issue or
announce the issuance or proposed issuance of any shares of common stock or common stock equivalents. In addition, on July
27, 2016, the Company terminated an aggregate of 5.5 million warrants with exercise prices of $1.21 and $1.25 per share (see Notes
2, 3 and 10 for additional details).